A blood test for patients who have been diagnosed with colorectal cancer
TARGET
Taking action against Colorectal Cancer Recurrence

There are approximately 1,000,000 colorectal cancer (CRC) survivors in the United States. Of the 140,000 newly diagnosed patients each year, 30-50% will experience a recurrence, with the majority developing within the first 2 to 3 years of initial treatment. Although the risk of recurrence varies by stage at time of diagnosis, more treatment options may be available when recurrence is detected early.

30-50% of patients will have a recurrence.

Most recurrences will happen within 2-3 yrs of initial treatment.

Although carcinoembryonic antigen (CEA) has been used for over five decades, the test can yield false negative results in some patients whose tumors may not secrete CEA, making it ineffective for monitoring those patients.

CEA may also yield false positive results that can be caused by smoking and other non-cancerous conditions such as inflammatory bowel disease (IBD), therefore making it essential to supplement CEA testing with other diagnostic tests to manage patient care.


Recent data shows that COLVERA detected 2x as many colorectal cancer recurrences compared to CEA, an identified residual and metastatic disease in patients who had undergone surgical resection.

By using COLVERA in combination with CEA, you and your doctor have more information to monitor your care more confidently and to determine whether additional follow-up, such as radiological imaging, should be considered.

DETECT
How does COLVERA work?

When cancer grows, the tumor can shed small pieces of DNA into the bloodstream. This DNA is known as circulating tumor DNA (ctDNA).

COLVERA can detect small amounts of ctDNA containing changes often seen in colorectal cancer but not in normal blood.

Testing with COLVERA is simple, designed to fit into your routine follow up care, and can be ordered and performed at the same time as CEA. By providing additional information of the presence of ctDNA, COLVERA may help to identify residual and recurrent CRC early when more treatment options are available.

COLVERA provides the added peace of mind by delivering simple and reliable results that will help you and your provider navigate your new normal.
PATIENT FINANCIAL ASSISTANCE

Clinical Genomics believes everyone should have access to innovative medical technology, and we are committed to ensuring that COLVERA is accessible and affordable.

We accept all insurance plans, and offer a patient financial assistance program with multiple options.

We are dedicated to excellence and are here to assist with any questions or concerns patients and family members may have.

To learn more about our assistance programs, contact us at:

Toll Free: 1-855-400-6919
billing@clinicalgenomics.com
colveratest.com

Clinical Genomics Pathology Inc.
A Clinical Genomics Inc. Company
1031 US Highway 202/206 Bridgewater, NJ 08807 USA
Customer Service: 1-855-870-0096 colveratest.com

COLVERA and the CLINICAL GENOMICS logo are trademarks or registered trademarks of Clinical Genomics Pty. Ltd., used under permission Clinical Genomics Pathology Inc., a Clinical Genomics Inc. Company.

For use under pending US patent applications.

EXTUS-395 [3]